
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is a clinical-stage biotechnology company with a promising drug candidate pipeline in the Wnt pathway, a critical mediator of tissue repair. With its lead candidate SZN-8141 showing positive preclinical data and approaching potential IND submission in 2H26, strong partnerships with established companies, and a recent research milestone achievement, the company is well-positioned for success in the retinal disease market. Financially, the company has a strong cash position and has shown disciplined expense management. The key question for investors now is whether the positive preclinical results will translate into successful clinical outcomes, which could lead to a significant increase in the company's valuation.
Bears say
Surrozen is heavily reliant on its preclinical drug candidates, SZN-8141, SZN-413, and SZN-8143, which are still in their early stages and have yet to demonstrate their clinical efficacy. With a highly competitive market for retinal disease treatments, it is uncertain if Surrozen's drugs will be able to differentiate and achieve peak commercial revenue. Additionally, the company's current cash reserves and future financing plans may not be sufficient to fund its operations and bring its drugs to market. As a result, we have a negative outlook on Surrozen's stock.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares